Open AccessEFFICIENCY AND PERFORMANCE OF THE USE OF RECOMBINANT INTERFERON GAMMA IN COMPLEX THERAPY OF INFLUENZA A(H1N1)PDM09 PATIENTS
Author(s) -
Т. В. Сологуб,
A. S Midikari,
V. N Agafonov,
A. A Suzdalcev,
V. V Tsvetkov
Publication year - 2017
Publication title -
èpidemiologiâ i infekcionnye bolezni
Language(s) - English
Resource type - Journals
eISSN - 2411-3026
pISSN - 1560-9529
DOI - 10.17816/eid42628
Subject(s) - medicine , oseltamivir , regimen , incidence (geometry) , disease , immunology , covid-19 , infectious disease (medical specialty) , physics , optics
In the period of the epidemic rise in the incidence rate of influenza in 2015-2016 on the basis of infectious hospitals in Simferopol, Arkhangelsk and Samara, there performed a multicenter to evaluate the effectiveness and economic feasibility of two alternative treatment regimens for influenza A (H1N1) pdm09 patients. The study included 88 patients with a laboratory-confirmed diagnosis of influenza A (H1N1)pdm09. Patients of the main group (n = 46) received complex therapy with the use of antiviral (oseltamivir) and immunomodulating (interferon gamma) agents. Patients of the control group (n = 40) received only antiviral therapy (oseltamivir). To assess the effectiveness and economic feasibility of the two different treatment regimens, the outcome of the disease was analyzed: the discharge the hospital up to the 10th day of the illness and no symptoms of the disease by the 3-6th day of treatment. The supplementation of recombinant interferon gamma in the treatment regimen of influenza A (H1N1) pdm09 patients was found to promote the faster release of catarrhal and respiratory symptoms of the disease: the absence of dry cough by the 3-6th day of treatment (RR = 1.43, 95% CI: 0.86 - 2.38), rhinitis (RR 1.21, 95% CI 1.05-1.40) and dyspnea (RR= 1.28, 95% CI: 1.06-1.54). In addition, the supplementation of recombinant interferon gamma in the treatment regimen of patients with influenza A (H1N1)pdm09 promoted a significant shortening of time of the recovery and discharge from the hospital (RR =1.39, 95% CI: 0.97 - 2.00). Clinical and economic analysis of the use of two alternative treatment regimens has shown the supplementation of recombinant interferon gamma in the therapy of influenza A (H1N1) pdm09 patients to be economically favorable